<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32301341</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>5-6</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>A novel mutation in the cleavage site N291 of TDP-43 protein in a familial case of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>463</StartPage><EndPage>466</EndPage><MedlinePgn>463-466</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2020.1752243</ELocationID><Abstract><AbstractText>Cytoplasmic aggregation of TAR-DNA binding protein (TDP-43) in Amyotrophic Lateral Sclerosis (ALS) and fronto-temporal lobar dementia (FTLD) is associated with post-translational modifications (PTM) and delocalization. Studies on postmortem brains of ALS and FTLD patients showed the existence of TDP-43 fragments that end at position N291. We report a new heterozygous mutation p.N291H in a familial case of ALS. Expression of the mutant protein in cell lines and primary motor neurons induces aggregate formation in the cytoplasm and reduces cell viability. The discovery of mutations at cleavage sites in TDP-43 in patients, which we reviewed here, is valuable for understanding the true role of the various TDP-43 fragments identified in patients and thus, for developing effective targeted therapies for ALS and FTLD treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chami</LastName><ForeName>Anna A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-5610-4947</Identifier><AffiliationInfo><Affiliation>UMR 1253, iBRAIN, Universit&#xe9; de Tours, Inserm, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beltran</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>UMR 1253, iBRAIN, Universit&#xe9; de Tours, Inserm, Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Neurologie, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1625-8845</Identifier><AffiliationInfo><Affiliation>UMR 1253, iBRAIN, Universit&#xe9; de Tours, Inserm, Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Neurologie, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andres</LastName><ForeName>Christian R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>UMR 1253, iBRAIN, Universit&#xe9; de Tours, Inserm, Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Biochimie et Biologie Mol&#xe9;culaire, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laumonnier</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>UMR 1253, iBRAIN, Universit&#xe9; de Tours, Inserm, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>UMR 1253, iBRAIN, Universit&#xe9; de Tours, Inserm, Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Biochimie et Biologie Mol&#xe9;culaire, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vourc'H</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UMR 1253, iBRAIN, Universit&#xe9; de Tours, Inserm, Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Biochimie et Biologie Mol&#xe9;culaire, Tours, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">TARDBP</Keyword><Keyword MajorTopicYN="N">fragments</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32301341</ArticleId><ArticleId IdType="doi">10.1080/21678421.2020.1752243</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>